PLASMA-RICH PLATELETS ANTI-INFLAMMATORY EFFECT IN CONDITIONS OF CARRAGEENAN-INDUCED PAW EDEMA IN RATS

Authors:

Abstract:

The purpose of the study was to determine the expression of platelet-rich plasma anti-inflammatory effect in conditions of its complex use in a model of carrageenan-induced paw edema in rats. Experimental studies were performed in conditions of carrageenan-induced exudative aseptic inflammation. Rats were undergone to separate and combined platelet-rich plasma and ellagic acid injections. Diclofenac sodium was used as a reference drug. The inflammatory response indexes, pro-inflammatory cytokine content, and inducible NO-synthase activity in the paw tissue of animals were determined 30 min, 1, 2, 4, and 6 hours after carrageenan administration. The data obtained revealed rats’ hind paw edema reduction, an inflammatory index decrease, and TNF and IL-1β release block after platelet-rich plasma and ellagic acid combined administration in conditions of carrageenan-induced aseptic inflammation. The investigated compound's anti-inflammatory effect was maximal at the delayed stages of inflammatory reaction, starting from 4 hours until the end of the trial. The authors proved the principal possibility of anti-inflammatory efficacy increasing as a result of platelet-rich plasma and ellagic acid combined administration in the form of additivity. The possibility of anti-inflammatory efficacy increasing by platelet-rich plasma added to a complex pharmacological regimen was demonstrated. The revealed platelet-rich plasma and ellagic acid combined administration anti-inflammatory efficacy and a pathogenetic background of this protective effect implementation in carrageenan-induced rat paw inflammation prove the reasonability of this pharmacological scheme anti-inflammatory efficacy clinical testing.

Keywords:

aseptic inflammation carrageenan rats paw edema ellagic acid platelet-rich plasma pathophysiological mechanisms pathogenetically oriented pharmacocorrection

References:

1. Klymenko MO. Nyzkostupeneve dyfuzne khronichne zapalennya. Aktualni problemy transportnoyi medytsyny. 2022; 3(69): 7–19. doi: http://dx.doi.org/10.5281/zenodo.7188166. [in Ukrainian].
2. Chernykh VV, Shebeko SK, Zupanets KO. Protyzapalni vlastyvosti standartyzovanoyi roslynnoyi kompozytsiyi BNO 2103 u shchuriv z flohohen-indukovanym nabryakom stopy. Farmakolohiya ta likarska toksykolohiya. 2022; 16(1): 57–66. doi: 10.33250/16.01.057. [in Ukrainian].
3. Shepeta YL, Lelyukh MI, Zimenkovsky BS, Nektegaev IO, Lesyk RB. Syntez ta otsinka protyzapalnoyi aktyvnosti pokhidnykh rodaninu z 2-(2,6-dykhlorofenilamino)fenilatsetamidnym frahmentom u molekulakh. Farmatsevtychnyy chasopys. 2018; 1: 6–16. doi: 10.11603/2312-0967.2018.1.8601. [in Ukrainian].
4. Antonelli M, Kushner I. It’s time to redefine inflammation. FASEB J. 2017; 31: 1787–1791. doi: https://doi.org/10.1096/fj.201601326R.
5. Čižmáriková M, Michalková R, Mirossay L, Mojžišová G, Zigová M, Bardelčíková A. et al. Ellagic Acid and Cancer Hallmarks: Insights from Experimental Evidence. Biomolecules. 2023; 13(11): 1653. doi: 10.3390/biom13111653.
6. Everts PA, van Erp A, DeSimone A, Cohen DS, Gardner RD. Platelet rich plasma in orthopedic surgical medicine. Platelets. 2021; 32(2): 163–174. doi: 10.1080/09537104.2020.1869717.
7. Gupta S, Paliczak A, Delgado D. Evidence-based indications of platelet-rich plasma therapy. Expert Rev Hematol. 2021; 14(1): 97–108. doi: 10.1080/17474086.2021.1860002.
8. Jeong S, Bae S, Shin EC, Lee JH, Ha JH. Ellagic Acid Prevents Particulate Matter-Induced Pulmonary Inflammation and Hyperactivity in Mice: A Pilot Study. Int J Environ Res Public Health. 2023; 20(5): 4523. doi: 10.3390/ijerph20054523.
9. Leńska-Mieciek M, Madetko-Alster N, Alster P, Królicki L, Fiszer U, Koziorowski D. Inflammation in multiple system atrophy. Front Immunol. 2023; 14: 1214677. doi: 10.3389/fimmu.2023.1214677.
10. Petryk N, Shevchenko O. Anti-inflammatory Activity of Mesenchymal Stem Cells in λ-Carrageenan-Induced Chronic Inflammation in Rats: Reactions of the Blood System, Leukocyte-Monocyte Ratio. Inflammation. 2020; 43(5): 1893–1901. doi: 10.1007/s10753-020-01262-5.
11. Qiao J, Guo X, Zhang L, Zhao H, He X. Autologous platelet rich plasma injection can be effective in the management of osteoarthritis of the knee: impact on IL-1β, TNF-α, hs-CRP. J Orthop Surg Res. 2024; 19(1): 703. doi: 10.1186/s13018-024-05060-9.
12. Roe K. An inflammation classification system using cytokine parameters. Scand J Immunol. 2021; 93(2): e12970. doi: 10.1111/sji.12970.
13. Schmidt M, Sørensen HT, Pedersen L. Cardiovascular risks of diclofenac versus other older COX-2 inhibitors (meloxicam and etodolac) and newer COX-2 inhibitors (celecoxib and etoricoxib): a series of nationwide emulated trials. Drug Saf. 2022; 45(9): 983–994. doi: 10.1007/s40264-022-01211-1.
14. Shahidi S, Komaki A, Raoufi S, Salehi I, Zarei M, Mahdian M. The Antinociceptive Effect of Ellagic Acid in Streptozotocin-induced Hyperglycemic Rats by Oxidative Stress Involvement. Basic Clin Neurosci. 2021; 12(6): 861–872. doi: 10.32598/bcn.2021.2413.1.
15. Vastyanov RS, Chekhlova OV. Pathophysiological model of indirect revascularization in rats with microangiopathy of limbs caused by experimental streptozocin diabetes. Reports of Morphology. 2019; 25(4): 24–29. doi: 10.31393/morphology-journal-2019-25(4)-04.

Publication:

«World of Medicine and Biology» Vol. 20 No. 90 (2024) , с. 170-175
УДК 616.379-008.64:616.137.86

DOI:

https://doi.org/10.26724/2079-8334-2024-4-90-170-175